PL-6983: The New Bremelanotide
In animal subjects, PL-6983 showed increased sexual activity but significantly lower increases in blood pressure than was seen with Bremelanotide, and heightened blood pressure is the concern cited by the FDA for not approving Bremelanotide to treat Erectile Dysfunction. Phase 1 Clinical Trials for this male and female libido enhancing drug will begin in the near future and it may eventually become the first true aphrodisiac available to the public... Visit the Bremelanotide Bulletin to learn more about PL-6983's future development or subscribe to its newsletter below....
* This website is in development and will
provide future updates about the progress of PL-6983. |
The PL-6983 compound is a new version of
Bremelanotide, a treatment for Female Sexual Arousal Disorder and Erectile
Dysfunction, in development by Palatin Technologies.